Brinker Capital Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Brinker Capital Investments’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63M	Buy	5,162 +1,945	+60%	+$458K	0.01%	908
2026 Q1	$642K	Sell	3,217 -284	-8%	-$56.2K	0.01%	1351
2025 Q4	$662K	Buy	3,501 +2,315	+195%	+$445K	﹤0.01%	1461
2025 Q3	$210K	Buy	+1,186	New	+$176K	﹤0.01%	1949
2022 Q1	–	Sell	-2,092	Closed	-$202K	–	1402
2021 Q4	$202K	Buy	+2,092	New	+$193K	﹤0.01%	1351

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brinker Capital Investments's LGND Position: Q2 2026 in Review

Brinker Capital Investments increased its Ligand Pharmaceuticals (LGND) stake by 60% in Q2 2026, buying an estimated $458K and bringing the position to 5,162 shares worth $1.63M. The position accounts for 0.01% of the portfolio, ranked #908.

Brinker Capital Investments first reported a position in LGND in Q4 2021 and has held it in 5 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Brinker Capital Investments held 5,162 shares of Ligand Pharmaceuticals worth $1.63M as of Q2 2026.
Brinker Capital Investments bought 1,945 Ligand Pharmaceuticals shares in Q2 2026, an estimated $458K.
Ligand Pharmaceuticals made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #908 holding.
Brinker Capital Investments first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.